Christophe Fermé

8.6k total citations · 2 hit papers
98 papers, 4.3k citations indexed

About

Christophe Fermé is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christophe Fermé has authored 98 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Pathology and Forensic Medicine, 45 papers in Oncology and 32 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christophe Fermé's work include Lymphoma Diagnosis and Treatment (85 papers), Lung Cancer Treatments and Mutations (28 papers) and Viral-associated cancers and disorders (23 papers). Christophe Fermé is often cited by papers focused on Lymphoma Diagnosis and Treatment (85 papers), Lung Cancer Treatments and Mutations (28 papers) and Viral-associated cancers and disorders (23 papers). Christophe Fermé collaborates with scholars based in France, Belgium and Netherlands. Christophe Fermé's co-authors include Hervé Tilly, Bertrand Coiffier, Christian Gisselbrecht, Gilles Salles, Catherine Thiéblemont, Franck Morschhauser, Éric Lepage, Catherine Sebban, Pierre Feugier and Dominique Bordessoule and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Christophe Fermé

92 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

2005 1.1k citations Pierre Feugier, Catherine Sebban et al. Journal of Clinical Oncology profile →
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

2010 1.1k citations Bertrand Coiffier, Catherine Thiéblemont et al. Blood profile →

Peers

Countries citing papers authored by Christophe Fermé

Since Specialization

Citations

This map shows the geographic impact of Christophe Fermé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Fermé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Fermé more than expected).

Fields of papers citing papers by Christophe Fermé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christophe Fermé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Fermé. The network helps show where Christophe Fermé may publish in the future.

Co-authorship network of co-authors of Christophe Fermé

This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Fermé. A scholar is included among the top collaborators of Christophe Fermé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Fermé. Christophe Fermé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dose-Adjusted Rituximab Mini-CYVE (CYtarabine bolus, VEpeside and dexamethasone) for Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Not Eligible for High Dose Therapy 2017 ·Blood ·(unknown), Jean‐Marie Michot, Julien Lazarovici, Khalil Saleh, David Ghez, Claude Chahine, Loïc Verlingue, Christophe Willekens, Véronique Vergé, Christophe Fermé, Alina Danu, Vincent Ribrag	0
2	Le lymphome de Hodgkin : stratégies thérapeutiques actuelles et futures 2017 ·Bulletin du Cancer ·Anthony Turpin, Jean‐Marie Michot, Emmanuelle Kempf, R. Mazeron, Peggy Dartigues, M. Terroir, (unknown), (unknown), Cristina Castilla‐Llorente, Téreza Coman, Alina Danu, David Ghez, Sylvain Pilorge, Julia Arfi‐Rouche, Laurent Dercle, Jean‐Charles Soria, Patrice Carde, Vincent Ribrag, Christophe Fermé, Julien Lazarovici	3
3	Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma 2017 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), M. Terroir, Julia Arfi‐Rouche, Jean‐Marie Michot, Sacha Mussot, (unknown), Maria‐Rosa Ghigna, Peggy Dartigues, (unknown), Alina Danu, Christophe Fermé, Vincent Ribrag, David Ghez	21
4	Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High-Dose Therapy with Stem Cell Transplantation in Poor-Risk Patients with Diffuse Large B Cell Lymphoma 2014 ·Biology of Blood and Marrow Transplantation ·Christophe Fruchart, Hervé Tilly, Franck Morschhauser, Hervé Ghesquières, Marie Bouteloup, Christophe Fermé, Éric Van Den Neste, Dominique Bordessoule, Réda Bouabdallah, Alain Delmer, Olivier Casasnovas, Loïc Ysebaert, Renaud Ciappuccini, Josette Brière, Christian Gisselbrecht	11
5	Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma 2013 ·Haematologica ·Emmanuel Bachy, Roch Houot, F. Morschhauser, Anne Sonet, Pauline Brice, Karim Belhadj, Guillaume Cartron, B. Audhuy, Christophe Fermé, Pierre Feugier, Catherine Sebban, Vincent Delwail, Hervé Maisonneuve, Steven Le Gouill, Sophie Lefort, Nicole Brousse, C. Foussard, Gilles Salles, (unknown)	60
6	Low-Dose Radiation Treatment in Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma: A Plausible Approach? A Single-Institution Experience in 10 Patients 2012 ·International Journal of Radiation OncologyBiologyPhysics ·T. Girinsky, A. Paumier, Christophe Fermé, (unknown), Vincent Ribrag, François Leroy-Ladurie, Mithra Ghalibafian	20
7	Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B) 2012 ·Annals of Oncology ·Nicolas Ketterer, (unknown), Catherine Thiéblemont, Christophe Fermé, J Brière, Olivier Casasnovas, Serge Bologna, B. Christian, Thierry Connerotte, Christian Récher, Dominique Bordessoule, Christophe Fruchart, Richard Delarue, Christophe Bonnet, F. Morschhauser, Bruno Anglaret, Carole Soussain, Bettina Fabiani, H. Tilly, Corinne Haïoun	21
8	Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte breakdown → 2010 ·Blood ·Bertrand Coiffier, Catherine Thiéblemont, Éric Van Den Neste, G. Lepeu, Isabelle Plantier, Sylvie Castaigné, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban, Karim Belhadj, Dominique Bordessoule, Christophe Fermé, Hervé Tilly	1071
9	Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B‐cell lymphoma 2009 ·Cancer ·Vincent Ribrag, Christian Gisselbrecht, Corinne Haïoun, Gilles Salles, (unknown), Marjan Ertault, Christophe Fermé, Josette Brière, Pauline Brice, Nicolas Mounier	45
10	Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study 2008 ·Blood ·Gilles Salles, Nicolas Mounier, Sophie de Guibert, Franck Morschhauser, Chantal Doyen, Jean‐François Rossi, Corinne Haïoun, Pauline Brice, Beatrice Mahé, Réda Bouabdallah, B. Audhuy, Christophe Fermé, Caroline Dartigeas, Pierre Feugier, Catherine Sebban, Luc Xerri, Charles Foussard	239
11	Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group 2008 ·Journal of Clinical Oncology ·Franck Morschhauser, Pauline Brice, Christophe Fermé, Marine Diviné, Gilles Salles, Réda Bouabdallah, Catherine Sebban, Laurent Voillat, Olivier Casasnovas, Aspasia Stamatoullas, Krimo Bouabdallah, Marc André, Jean-Philippe Jaı̈s, Dominique Cazals‐Hatem, Christian Gisselbrecht	90
12	CHOP Alone Compared With CHOP Plus Radiotherapy for Localized Aggressive Lymphoma in Elderly Patients: A Study by the Groupe d’Etude des Lymphomes de l’Adulte 2007 ·Journal of Clinical Oncology ·Christophe Bonnet, Georges Fillet, Nicolas Mounier, G. Ganem, Thierry Jo Molina, Catherine Thiéblemont, Christophe Fermé, Bruno Quesnel, C. Martin, Christian Gisselbrecht, Hervé Tilly, Félix Reyes	161
13	Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2 2007 ·Annals of Oncology ·Pierre Morel, Philippe Gaulard, Christian Gisselbrecht, Christophe Fermé, Gilles Salles, Hervé Tilly, Josette Brière, MC Copin, P Lederlin, Olivier Hermine, Ivan Théate, Corinne Haïoun, Nicolas Mounier	5
14	Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation 2005 ·Leukemia & lymphoma ·Elias Jabbour, (unknown), P Arnaud, Christophe Fermé, Patrice Carde, (unknown), (unknown), JH Bourhis, Serge Koscielny, Vincent Ribrag	10
15	Outcome of Elderly Patients with Aggressive Non-Hodgkin's Lymphoma Refractory to or Relapsing after First-line CHOP or CHOP-like Chemotherapy: A Low Probability of Cure 2004 ·Leukemia & lymphoma ·Elias Jabbour, (unknown), Florence Suzan, (unknown), Călin Cainap, N. Toumi, Christophe Fermé, Patrice Carde, Vincent Ribrag	15
16	Complications à long terme du traitementde la maladie de Hodgkin 2000 ·Hématologie ·Christophe Fermé	0
17	Quality of life assessment in Hodgkin’s disease: A new comprehensive approach 1998 ·Annals of Oncology ·Hans‐Henning Flechtner, Jens Ulrich Rüffer, M. Henry‐Amar, W. A. M. Mellink, M. Sieber, Christophe Fermé, Houchingue Eghbali, Andreas Josting, Volker Diehl	27
18	Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients 1996 ·Cancer ·Pauline Brice, Y Bastion, Marine Diviné, G. Nedellec, Augustin Ferrant, Jean Gabarre, Oumédaly Reman, Éric Lepage, Christophe Fermé	3
19	Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients 1996 ·Cancer ·Pauline Brice, Y Bastion, Marine Diviné, G. Nedellec, Augustin Ferrant, Jean Gabarre, Oumédaly Reman, Éric Lepage, Christophe Fermé	56
20	Maladie de Hodgkin. Masses résiduelles histologiquement non évolutives après chimiothérapie. 1984 ·La Presse Médicale ·Éric Lepage, Christophe Fermé, J Frija, Brice Gayet, (unknown), M F D'Agay, C Gisselbrecht, Marc Marty, M Boiron	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact